Mylotarg: antibody-targeted chemotherapy comes of age

@article{Sievers2001MylotargAC,
  title={Mylotarg: antibody-targeted chemotherapy comes of age},
  author={E. Sievers and M. Linenberger},
  journal={Current Opinion in Oncology},
  year={2001},
  volume={13},
  pages={522-527}
}
  • E. Sievers, M. Linenberger
  • Published 2001
  • Medicine
  • Current Opinion in Oncology
  • Mylotarg (gemtuzumab ozogamicin, CMA-676; Wyeth-Ayerst Laboratories, Philadelphia, PA) recently was approved by the US Food and Drug Administration for the treatment of patients with CD33-positive acute myeloid leukemia in first relapse, age 60 years or older, who are not considered candidates for other types of cytotoxic chemotherapy. In combined phase II studies of 142 patients with CD33-positive acute myeloid leukemia in first relapse, Mylotarg monotherapy was associated with a 30% overall… CONTINUE READING
    Gemtuzumab Ozogamicin
    • 10
    Efficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates
    • 105
    • PDF
    Targeted therapy for hematologic malignancies.
    • 8
    • PDF

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 29 REFERENCES